Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
68.41 K
Value Traded
174.91 K
Short % Float
0.01%
-5.63%Week
-42.37%1 Month
-66.89%3 Month
-54.65%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
846.75 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
560.34 M
Float Shares
226.91 M
Insiders
59.54%
Institutions
0.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SLBT Catalyst Timeline
Dated clinical, regulatory and corporate events for SL Science Holding Limited Ordinary Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for SL Science Holding Limited Ordinary Shares
28Total events
2Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
Event history 22
▲Preclinical PoCPreclinical
Preclinical data show γδ T cells preferentially kill chemotherapy-resistant MGMT-positive glioblastoma cells
glioblastomasource ↗
●Manufacturing MilestoneCMC / Inspection
FDA Drug Master File filed for GDT cell-derived exosomes
●Other Regulator MilestoneEx-US Regulatory
Drug Master File for GDT cell-derived exosomes submitted to FDA
●PublicationPresentation
Peer-reviewed publication outlining clinical development requirements for γδ T cell modality
glioblastomasource ↗
◆Oral PresentationVdelta2Presentation
Presentation at WCP 2026: Intracranial γδ T Cell Therapy Eliminates Glioblastoma in Preclinical Models
glioblastoma multiforme (GBM)source ↗
▲Oral PresentationPresentation
Presentation of preclinical gamma delta T cell research at WCP 2026
glioblastomasource ↗
◆Orphan Drug DesignationVdelta2Designation
Orphan Drug Designation request submitted to FDA for Vdelta2+ Gamma Delta T Cells in GBM
glioblastoma multiforme (GBM)source ↗
●Oral PresentationγδTPresentation
Preclinical intracranial γδT cell therapy data presented at World Conference on Basic and Clinical Pharmacology
glioblastomasource ↗
●Preclinical PoCPreclinical
Preclinical research on intracranial γδT cell therapy exhibited at World Congress
glioblastomasource ↗
●Poster PresentationPresentation
Preclinical research exhibited at World Congress in Melbourne
glioblastomasource ↗
●Oral PresentationPresentation
July presentation in Melbourne demonstrating in vivo tumor growth control
solid tumorssource ↗
◆Orphan Drug DesignationVdelta2Designation
Orphan Drug Designation request under FDA review
glioblastoma multiformesource ↗
▲Orphan Drug DesignationVdelta2Designation
Orphan drug designation application submitted for Vdelta2+ γδT cell therapy
glioblastomasource ↗
Past FDA Catalysts and PDUFA Decisions
How SLBT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-12 | Vdelta2+ Gamma Delta T Cells | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SLBT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wang Ching-DongDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 4,545,306 333,832,129 held | $0.00 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLBT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SLBT for Q2 2026. | ||||
SLBT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLBT ranks across every disease it competes in
Competitive Position is a premium feature
See how SLBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLBT News
-SLBT
Sep 24, 2026▼ -6%on this newsshared move
SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma
SL Science presented promising preclinical data on its unmodified γδ T cell therapy targeting chemotherapy-resistant glioblastoma at the Japanese Cancer Association meeting. The therapy demonstrated preferential cytotoxicity towards MGMT-positive tumor cells, rapid tumor elimination, and superior efficacy compared to conventional T cells. The findings suggest a potential new treatment pathway for patients with resistant glioblastoma.
Read more →-SLBT
Sep 2, 2026SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
SL Science Holding Limited celebrated its first quarter as a publicly traded company by ringing the Nasdaq bell. The company has made significant progress in its Gamma Delta T cell platform, particularly in glioblastoma treatment, and is currently preparing additional data for the FDA's review of its Orphan Drug Designation request. Management emphasizes the potential of their therapies in revolutionizing cancer treatment.
Read more →-SLBT
Aug 27, 2026SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
SL Science has filed a new Drug Master File (DMF) with the FDA for Gamma Delta T cell-derived exosomes. This filing enhances the regulatory framework for the company's innovative therapies, particularly in oncology. The exosomes are noted for their ability to cross the blood-brain barrier, offering potential solutions for treating glioblastoma. This development is expected to streamline future regulatory processes and reduce bottlenecks in cell therapy development.
Read more →-SLBT
Aug 11, 2026▼ -5.7%on this newsshared move
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
SL Science Holding Limited has published a peer-reviewed article outlining a framework for the clinical development of γδ T cell therapy in glioblastoma. Co-authored with Taipei Medical University, the article details necessary clinical trial designs and biological measurements. This framework aims to bridge laboratory findings with clinical outcomes, emphasizing the need for rigorous evidence generation in human trials.
Read more →-SLBT
Jul 17, 2026SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
SL Science showcased groundbreaking research on glioblastoma treatment at the 2026 World Congress of Basic and Clinical Pharmacology. The study demonstrated the effectiveness of gamma delta T cells in eliminating tumors in preclinical models. Key highlights included complete tumor eradication and a favorable safety profile, emphasizing the potential of this innovative therapy.
Read more →-SLBT
Jul 10, 2026SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
SL Science Holding Limited has submitted an Orphan Drug Designation request to the FDA for its GDT cell therapy targeting glioblastoma multiforme. This submission acknowledges the critical unmet medical need in treating this aggressive brain cancer. The therapy's unique mechanism allows it to engage tumor cells directly, potentially improving treatment outcomes. The company aims to advance its GDT platform towards clinical development.
Read more →-SLBT
Jun 19, 2026▼ -21.9%on this news
SL Science Holding Limited Reports Full Year 2025 Financial Results
SL Science Holding Limited has reported its full year 2025 financial results, highlighting progress in its Gamma Delta T Cell and CD-19 Armed-T therapy platforms. The company is focused on expanding its oncology pipeline and enhancing its clinical development capabilities. Additionally, SL Science aims to accelerate its global growth following its recent Nasdaq listing.
Read more →-SLBT
Jun 14, 2026SL Science Holding Limited Completes Business Combination and Lists on the Nasdaq Global Market (Formerly known as SL BIO Ltd.)
SL Science Holding Limited, previously known as SL BIO Ltd., has successfully completed its business combination and is now trading on the Nasdaq Global Market as SLBT. The company focuses on developing allogeneic GDT cell-based therapies aimed at treating pancreatic cancer and glioblastoma. This advancement marks a significant step in their therapeutic offerings.
Read more →-SLBT
Jun 12, 2026BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
SL BIO Ltd. has successfully closed its business combination with Horizon Space Acquisition II, transitioning to a publicly traded entity under the new Nasdaq ticker SLBT. This merger, valued at approximately $5.568 billion, includes a $7.8 million PIPE financing aimed at accelerating the company's growth. SL Bio specializes in innovative cellular and gene therapies, with a plan to scale cell therapy into a more standardized and globally applicable model. The company's leadership is backed by an experienced board, positioned to guide its future initiatives in the biopharmaceutical sector.
Read more →-SLBT
Jan 14, 2026SL BIO Ltd. and Horizon Space Acquisition II Corp. Announce Registration Statement Effectiveness and Extraordinary General Meeting Date to Approve Business Combination
SL BIO Ltd. and Horizon Space Acquisition II Corp. have announced that their registration statement related to a proposed business combination has been declared effective by the SEC. This marks a significant step forward in the merger process. The business combination aims to enhance SL Bio's capabilities in developing cellular and gene therapies.
Read more →About SL Science Holding Limited Ordinary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next SLBT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime